 Immuron executes a Research Agreement with The Henry M. Jackson Foundation for Advancement of Military Medicine Inc. MELBOURNE, Australia, June 19, 2020 GLOBE NEWSWIRE -- Immuron Limited ASX: IMC; NASDAQ: IMRN, an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, today is pleased to provide shareholders with an update on the progress made to date on the companys research collaboration with the Naval Medical Research Center NMRC previously announced in October 2019. 